Concepedia

H. Wakelee

HW

Statistics

Publications

4

Citations

296

H-Index

4

Active since

2022

Affiliations

NewYork–Presbyterian Hospital(Current)

Stanford University

Roche (United Kingdom)

Cornell University

Shanghai Pulmonary Hospital

H. Wakelee is an author at NewYork–Presbyterian Hospital specializing in oncology, medicine, and medical oncology.

Publications per year

2022–2024

4

Publications

4

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. · Annals of Oncology · 2023 · 251 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

Enriqueta Felip, M. Srivastava, Martin Reck et al. · Immuno-Oncology Technology · 2022 · 20 citations · Full text

Medicine, Oncology, Surgery +16

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

Enriqueta Felip, Nassar Altorki, Chi Zhou et al. · Annals of Oncology · 2022 · 14 citations

Medicine, Oncology, Pharmacology +10

1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

H. Wakelee, Martin Reck, Enriqueta Felip et al. · Annals of Oncology · 2024 · 11 citations · Full text

Medicine, Oncology, Pharmacology +8

1–4 of 4